查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006274

兽药市场：2026-2032年全球市场预测（依产品类型、疾病类型、目标动物、剂型、给药途径及最终用户划分）

Livestock Medicine Market by Product Type, Disease Type, Animal Type, Formulation, Route of Administration, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，畜牧药品市场价值将达到 208.2 亿美元，到 2026 年将成长至 219.5 亿美元，到 2032 年将达到 307.2 亿美元，复合年增长率为 5.71%。

主要市场统计数据
基准年 2025 208.2亿美元
预计年份：2026年 219.5亿美元
预测年份 2032 307.2亿美元
复合年增长率 (%) 5.71%

对当前趋势和影响全球畜牧药品市场的关键驱动因素进行全面深入的洞察。

近年来，兽药产业经历了显着的变革，这主要受全球对动物性蛋白质需求不断增长、抗生素抗药性监管要求日益严格以及生产效率提升的推动。随着畜牧业规模的扩大以满足消费者需求，生产者和兽医面临越来越大的压力，他们需要采用先进的治疗方法，既要保障动物健康，又要维护公众安全。此外，药物製剂和给药系统的持续创新也拓展了治疗选择的范围，以应对包括细菌感染疾病、寄生虫感染和代谢紊乱在内的各种健康挑战。

重新定义畜牧业健康管理策略，探索推动兽医学创新的关键变革因素。

过去十年，兽医学的格局因一系列变革性因素而重塑，这些因素的影响远超传统的药物创新。精准畜牧技术已成为现代畜群健康管理的基石，透过即时监测生理指标和环境状况，能够主动预防健康威胁。同时，数位平台和云端分析技术的融合，为兽医和畜牧养殖户提供了数据驱动的决策工具，从而能够进行更精准的干预并优化治疗方案。

评估 2025 年美国对牲畜药品和贸易进行关税调整所带来的连锁经济和营运影响。

美国于2025年实施的新关税措施对兽药的整个供应链和定价结构产生了一系列连锁反应。关键活性成分和成品进口关税的提高推高了国内製药企业的生产成本，迫使它们寻求替代采购管道并与供应商重新谈判合约。因此，欧洲和亚洲的区域製造地已成为筹资策略的关键枢纽，前置作业时间和物流韧性成为采购团队的核心考量。

多方面的细分洞察，揭示了产品类型、疾病类型、动物种类、剂型和最终用户的不同需求模式。

为了解兽药市场的广泛性，有必要详细检视各个细分维度的需求分布。每个维度都反映了独特的治疗需求和应用场景。从产品类型来看，抗发炎药、抗生素、驱虫药、饲料添加剂、荷尔蒙以及各种疫苗是市场的主要支柱。抗生素产品包括头孢菌素类、青霉素类和四环霉素，抗寄生虫药物涵盖了体内外寄生虫控製剂。同时，饲料添加剂以益生元和益生菌製剂为主，激素分为促进生长激素和促生殖激素，疫苗技术则包括灭活疫苗、减毒活病毒疫苗和次单位疫苗。

美洲、欧洲、中东和非洲以及亚太地区兽药引进趋势和市场动态的区域差异分析

区域趋势在兽药产品组合的建构中发挥着至关重要的作用，经济状况和监管环境的差异决定了药物的普及率和治疗重点。在美洲，北美和南美强大的生产体係日益支持精准医疗方法的推广应用，这得益于对数位医疗基础设施的大量投资以及先进的抗菌药物合理使用政策。跨境贸易协定和区域协调努力进一步扩大了先进动物医药的可及性，并创造了一个以产品快速上市和合作研究为特征的竞争倡议。

分析推动畜牧治疗领域竞争优势和技术进步的产业先驱和策略合作伙伴关係。

在竞争激烈的市场环境中，一些产业相关人员正透过强大的研发开发平臺和策略合作伙伴关係来强化其治疗产品组合，从而脱颖而出。全球领先的兽药公司正利用生物技术和数位健康领域的跨学科专长，开发新一代疫苗、长效製剂和精准给药平台。同时，一些专注于特定领域的生物技术企业正寻求透过专注于抗寄生虫生技药品和基于微生物组的饲料添加剂等细分市场来打开市场。

为畜牧业健康产业的领导者提供切实可行的策略建议，以实现永续成长和市场主导。

为了在不断变化的市场环境中蓬勃发展，行业领导者应优先投资于数位健康基础设施和精准动物饲养解决方案。增强的即时监测能力和数据分析框架能够实现更积极主动的疾病管理，从而减少药物浪费并改善动物福利。同时，建立包含疫苗和益生菌等替代疗法的综合抗菌药物管理方案，有助于加强监管合规性和公众信任。

本报告详细介绍了构成本报告基础的严谨调查方法，包括资料来源、分析架构和检验技术。

本报告基于严谨的调查方法，整合了二手数据和一手数据，以提供全面可靠的分析。二手研究包括对科学论文、政府法规、行业白皮书和公开的企业资讯披露进行广泛审查，从而深入了解市场动态、技术趋势和监管环境。

总结了关键发现和对相关人员在不断变化的畜牧药品和兽药领域中应遵循的策略意义。

在不断变化的法规环境、技术突破和消费者期望的推动下，兽医学领域已开启一个充满活力的新时代。主要发现包括：数位健康解决方案的变革力量、合理使用抗生素的关键性，以及在关税压力下建立多元化价值链的策略必要性。此外，详细的細項分析揭示了不同疾病类型、动物类别、製剂偏好和终端使用者群体对产品和服务的不同需求，凸显了精准商业策略的价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：兽药市场：依产品类型划分

  • 抗发炎药
  • 抗生素
    • 头孢菌素
    • 青霉素
    • 四环霉素
  • 杀虫剂
    • 体外寄生虫控製剂
    • 体内寄生虫控製剂
  • 饲料添加剂
    • 益生元
    • 益生菌
  • 荷尔蒙
    • 生长激素
    • 生殖荷尔蒙
  • 疫苗
    • 灭活疫苗
    • 减毒活病毒疫苗
    • 次单位疫苗

第九章：兽药市场：依疾病类型划分

  • 感染疾病
  • 代谢性疾病
  • 营养缺乏
  • 寄生虫病
  • 生殖疾病

第十章：兽药市场：依目标动物划分

  • 水产养殖
  • 牛
  • 山羊
  • 家禽
  • 羊
  • 猪

第十一章：兽药市场：以剂型划分

  • 胶囊
  • 凝胶
  • 液体
  • 粉末
  • 药片

第十二章：兽药市场：依给药途径划分

  • 吸入
  • 注射药物
    • 肌肉内部
    • 静脉
  • 口服
    • 液体
    • 药片
  • 外用
    • 奶油
    • 修补

第十三章：兽药市场：依最终用户划分

  • 畜牧业的棋子
  • 动物诊所
  • 动物医院

第十四章：兽药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：兽药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：兽药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国兽药市场

第十八章：中国兽药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anicon Labor GmbH by SAN Group GmbH
  • AniCura Group by Mars Petcare
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Calier Laboratories SA
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Inc.
  • HESTER BIOSCIENCES LIMITED
  • HIPRA SA
  • Indian Immunologicals Ltd.
  • Koninklijke DSM NV
  • Merck KGaA
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Parnell Pharmaceuticals Holdings Ltd.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Vetpharma Animal Health SL
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-FE3E5C0AE72F

The Livestock Medicine Market was valued at USD 20.82 billion in 2025 and is projected to grow to USD 21.95 billion in 2026, with a CAGR of 5.71%, reaching USD 30.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.82 billion
Estimated Year [2026] USD 21.95 billion
Forecast Year [2032] USD 30.72 billion
CAGR (%) 5.71%

Setting the Stage for Comprehensive Insights into the Current Dynamics and Key Drivers Shaping Livestock Medicine Markets Globally

In recent years, the livestock medicine sector has undergone a period of remarkable transformation driven by escalating global demand for animal protein, stringent regulatory requirements regarding antimicrobial resistance, and heightened focus on production efficiency. As livestock populations expand to meet consumption needs, producers and veterinarians alike are under mounting pressure to adopt advanced therapeutic interventions that ensure animal health while safeguarding public safety. Moreover, continuous innovation in pharmacological formulations and delivery systems has broadened the therapeutic toolkit available to address a spectrum of health challenges spanning bacterial infections, parasitic infestations, and metabolic disorders.

Moving forward, understanding the confluence of demographic shifts, policy frameworks, and scientific breakthroughs is critical for stakeholders seeking to navigate this dynamic environment. Analysts and decision-makers must consider how emerging disease threats, evolving animal husbandry practices, and sustainability imperatives intersect to shape investment priorities and commercial strategies. By providing a comprehensive overview of current market dynamics and emerging patterns, this executive summary lays the foundation for a deeper exploration of critical industry trends, regulatory influences, and segmentation nuances. Through a structured narrative, readers will gain clarity on the forces accelerating change, the areas of greatest opportunity, and the potential obstacles that may temper growth. This introduction sets the stage for a nuanced examination of transformative shifts, tariff impacts, segmentation insights, and strategic recommendations presented in subsequent sections.

Exploring the Major Transformative Forces Redefining Livestock Health Management Strategies and Driving Innovation Across Veterinary Medicine

Over the past decade, the livestock medicine landscape has been reshaped by a constellation of transformative forces that extend beyond traditional pharmaceutical innovation. Precision livestock farming technologies have emerged as a cornerstone of modern herd health management, enabling real-time monitoring of physiological indicators and environmental conditions to preemptively address health threats. Simultaneously, the integration of digital platforms and cloud-based analytics has empowered veterinarians and farmers with data-driven decision-making tools, fostering more targeted interventions and optimized treatment regimens.

In parallel, growing regulatory scrutiny around antimicrobial resistance has catalyzed the development of alternative therapeutics such as vaccines, probiotics, and novel antiparasitic agents. Breakthroughs in subunit and live attenuated vaccine formulations have significantly reduced the reliance on broad-spectrum antibiotics, while advancements in formulation science have improved bioavailability and compliance through innovative delivery mechanisms. Lastly, increasing consumer awareness of animal welfare and sustainable agriculture practices is driving demand for hormone-free feed additives and environmentally responsible pharmaceuticals, prompting industry stakeholders to redefine their research and development priorities.

Assessing the Cascading Economic and Operational Consequences of 2025 United States Tariff Adjustments on Livestock Pharmacy and Trade

The implementation of new tariff measures in 2025 by the United States has introduced a series of ripple effects throughout the livestock medicine supply chain and pricing structures. Heightened import duties on key active pharmaceutical ingredients and finished products have elevated production costs for domestic formulators, compelling manufacturers to explore alternative sourcing corridors and renegotiated supplier agreements. As a result, regional manufacturing hubs in Europe and Asia are emerging as critical pivot points for procurement strategies, with lead times and logistical resilience becoming central considerations for procurement teams.

Moreover, downstream distributors and veterinary service providers are experiencing compressed margins due to escalated acquisition costs, which in turn has triggered a reassessment of pricing models and inventory management practices. These shifts have also accelerated the exploration of local API production and co-manufacturing partnerships as viable cost-mitigation approaches. Although short-term disruptions have tested the adaptability of established supply chains, they have simultaneously fostered a climate of strategic collaboration between governments, research institutions, and private sector actors aiming to enhance domestic API capabilities and reduce tariff vulnerabilities.

Uncovering Multidimensional Segmentation Insights That Illuminate Varied Demand Patterns by Product Type Disease Type Animal Type Formulation and End User

Understanding the breadth of livestock medicine requires a closer look at how demand diverges across multiple segmentation dimensions, each reflecting distinct therapeutic needs and usage scenarios. From a product type perspective, anti-inflammatory agents, antibiotics, antiparasitic agents, feed additives, hormones, and a diverse array of vaccines serve as the core pillars of the market. Antibiotic offerings span cephalosporins, penicillins, and tetracyclines, while antiparasitic portfolios include both ectoparasiticides and endoparasiticides. Meanwhile, feed additives are enriched with prebiotic and probiotic formulations, hormones are classified into growth and reproductive categories, and vaccine technologies encompass inactivated, live attenuated, and subunit options.

When viewed through the lens of disease type, infectious diseases lead the therapeutic agenda, followed by targeted interventions for metabolic disorders, nutritional deficiencies, parasitic infestations, and reproductive ailments. Animal type segmentation underscores differentiated requirements across aquaculture operations, cattle ranching, goat herding, poultry facilities, sheep farms, and swine production systems. Formulation preferences range from capsules and gels to liquids, powders, and tablets, each tailored to stability and ease of administration. Route of administration insights further nuance treatment selection with inhalation therapies, injectable options subdivided into intramuscular and intravenous formats, oral solutions available as liquids and tablets, and topical applications delivered via creams and patches. Finally, end users such as livestock farmers, veterinary clinics, and veterinary hospitals each exert unique purchasing behaviors and service expectations, driving targeted commercial strategies across the value chain.

Analyzing Regional Variations in Livestock Pharmaceutical Adoption Trends and Market Dynamics Across Americas EMEA and Asia-Pacific Territories

Regional dynamics play a crucial role in shaping livestock medicine portfolios, with divergent economic landscapes and regulatory frameworks dictating adoption rates and therapeutic priorities. In the Americas, robust production systems in North and South regions are increasingly adopting precision medicine approaches, supported by substantial investment in digital health infrastructure and progressive antimicrobial stewardship policies. Cross-border trade agreements and regional harmonization efforts further amplify access to advanced veterinary pharmaceuticals, fostering a competitive environment marked by rapid product launches and collaborative research initiatives.

Across Europe, the Middle East, and Africa, stakeholders navigate a complex tapestry of regulatory requirements, ranging from stringent European Union directives on drug residues to rapidly evolving guidelines in emerging African markets. The push for sustainable livestock practices in Europe is driving demand for organic and residue-free alternatives, while Middle Eastern regions are leveraging public-private partnerships to bolster local manufacturing capabilities. Conversely, Asia-Pacific represents a growth engine fueled by expanding aquaculture and poultry operations, with countries such as China and India spearheading large-scale adoption of vaccines and antiparasitic agents. Evolving infrastructures, increasing veterinary service penetration, and government incentives for biosecurity measures are key factors accelerating market uptake across this diverse region.

Profiling Pioneering Industry Participants and Strategic Alliances Driving Competitive Advantage and Technological Advancement in Livestock Therapeutics

Within this competitive landscape, certain industry participants have distinguished themselves through robust R&D pipelines and strategic collaborations that enhance their therapeutic portfolios. Leading global animal health companies are leveraging cross-disciplinary expertise in biotechnology and digital health to develop next-generation vaccines, long-acting formulations, and precision administration platforms. At the same time, specialized biotech ventures are making inroads by focusing on niche segments such as antiparasitic biologics and microbiome-based feed enhancers.

Strategic alliances between pharmaceutical firms and contract research organizations are accelerating clinical trial execution, regulatory submissions, and post-market surveillance activities. This trend is complemented by partnerships with academic institutions that provide early-stage innovation, ensuring a steady flow of novel compounds and delivery technologies. Additionally, emerging players in regional markets are capitalizing on localized manufacturing advantages and tailored formulations to address endemic disease profiles, thereby carving out differentiated market positions. Collectively, these varied approaches are redefining competitive dynamics and underscoring the importance of agility, innovation, and collaboration in sustaining long-term growth trajectories.

Presenting Actionable Strategic Recommendations to Equip Livestock Health Industry Leaders with Practical Pathways for Sustainable Growth and Market Leadership

To thrive amid evolving market conditions, industry leaders should prioritize investment in digital health infrastructures and precision livestock farming solutions. Enhancing real-time monitoring capabilities and data analytics frameworks will enable more proactive disease management, reduce therapeutic waste, and improve animal welfare outcomes. Simultaneously, establishing comprehensive antimicrobial stewardship programs that incorporate alternative therapies such as vaccines and probiotics will strengthen both regulatory compliance and public trust.

Moreover, diversifying supply chain networks through strategic partnerships with regional manufacturers and contract API producers can mitigate tariff-related risks while enhancing operational resilience. Expanding into high-growth segments, including aquaculture and poultry, requires tailored product development and targeted marketing strategies that address specific disease profiles and end-user requirements. Finally, fostering collaborative research initiatives with academic and governmental agencies will accelerate the advancement of novel therapeutics, drive cost efficiencies in clinical development, and fortify the innovation pipeline for sustained competitive differentiation.

Detailing Rigorous Research Methodology Encompassing Data Collection Sources Analytical Frameworks and Validation Techniques Underpinning the Report

This report is grounded in a rigorous research methodology that synthesizes both secondary and primary data sources to deliver a comprehensive and reliable analysis. Secondary research encompassed an extensive review of scientific publications, government regulations, industry white papers, and publicly available company disclosures to establish foundational insights into market dynamics, technological trends, and regulatory landscapes.

Primary research efforts included structured interviews with senior executives, veterinary practitioners, supply chain managers, and end-user stakeholders, providing firsthand perspectives on current challenges, purchasing behaviors, and innovation priorities. Data validation processes involved cross-referencing reported financials, product launch announcements, and patent filings to ensure consistency and accuracy. Analytical frameworks such as SWOT analysis, PESTLE evaluation, and Porter's Five Forces were applied to contextualize competitive positioning, identify growth drivers and barriers, and project strategic implications without the inclusion of specific market sizing or forecasting figures.

Summarizing Key Findings and Strategic Implications for Stakeholders Navigating the Evolving Landscape of Livestock Medicine and Veterinary Care

The convergence of evolving regulatory environments, technological breakthroughs, and shifting consumer expectations has set the stage for a dynamic era in livestock medicine. Key discoveries include the transformative power of digital health solutions, the critical importance of antimicrobial stewardship, and the strategic necessity of diversified supply chains in the face of tariff pressures. Additionally, in-depth segmentation analyses reveal distinct product and service requirements across disease types, animal categories, formulation preferences, and end-user profiles, underscoring the value of targeted commercial strategies.

As regional markets continue to diverge in terms of regulatory rigor and infrastructural readiness, stakeholders must adopt flexible approaches that balance global best practices with local market realities. By integrating strategic partnerships, embracing innovation-driven collaborations, and reinforcing data-driven decision-making processes, industry participants can position themselves to capitalize on emerging opportunities while navigating potential disruptions. This executive summary has distilled the essential insights necessary to inform strategic planning and guide resource allocation, paving the way for more resilient and responsive operations in the livestock medicine sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Livestock Medicine Market, by Product Type

  • 8.1. Anti-inflammatory Agents
  • 8.2. Antibiotics
    • 8.2.1. Cephalosporins
    • 8.2.2. Penicillins
    • 8.2.3. Tetracyclines
  • 8.3. Antiparasitic Agents
    • 8.3.1. Ectoparasiticides
    • 8.3.2. Endoparasiticides
  • 8.4. Feed Additives
    • 8.4.1. Prebiotics
    • 8.4.2. Probiotics
  • 8.5. Hormones
    • 8.5.1. Growth Hormones
    • 8.5.2. Reproductive Hormones
  • 8.6. Vaccines
    • 8.6.1. Inactivated Vaccines
    • 8.6.2. Live Attenuated Vaccines
    • 8.6.3. Subunit Vaccines

9. Livestock Medicine Market, by Disease Type

  • 9.1. Infectious Diseases
  • 9.2. Metabolic Diseases
  • 9.3. Nutritional Deficiency Diseases
  • 9.4. Parasitic Diseases
  • 9.5. Reproductive Diseases

10. Livestock Medicine Market, by Animal Type

  • 10.1. Aquaculture
  • 10.2. Cattle
  • 10.3. Goats
  • 10.4. Poultry
  • 10.5. Sheep
  • 10.6. Swine

11. Livestock Medicine Market, by Formulation

  • 11.1. Capsules
  • 11.2. Gels
  • 11.3. Liquids
  • 11.4. Powders
  • 11.5. Tablets

12. Livestock Medicine Market, by Route of Administration

  • 12.1. Inhalation
  • 12.2. Injectable
    • 12.2.1. Intramuscular
    • 12.2.2. Intravenous
  • 12.3. Oral
    • 12.3.1. Liquids
    • 12.3.2. Tablets
  • 12.4. Topical
    • 12.4.1. Creams
    • 12.4.2. Patches

13. Livestock Medicine Market, by End Users

  • 13.1. Livestock Farmers
  • 13.2. Veterinary Clinics
  • 13.3. Veterinary Hospitals

14. Livestock Medicine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Livestock Medicine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Livestock Medicine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Livestock Medicine Market

18. China Livestock Medicine Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Anicon Labor GmbH by SAN Group GmbH
  • 19.6. AniCura Group by Mars Petcare
  • 19.7. Biogenesis Bago SA
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Calier Laboratories S.A.
  • 19.10. Ceva Sante Animale
  • 19.11. Dechra Pharmaceuticals PLC
  • 19.12. Elanco Animal Health Inc.
  • 19.13. HESTER BIOSCIENCES LIMITED
  • 19.14. HIPRA S.A.
  • 19.15. Indian Immunologicals Ltd.
  • 19.16. Koninklijke DSM N.V.
  • 19.17. Merck KGaA
  • 19.18. Neogen Corporation
  • 19.19. Norbrook Laboratories Ltd.
  • 19.20. Parnell Pharmaceuticals Holdings Ltd.
  • 19.21. Phibro Animal Health Corporation
  • 19.22. Vetoquinol S.A.
  • 19.23. Vetpharma Animal Health S.L.
  • 19.24. Virbac SA
  • 19.25. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVESTOCK MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVESTOCK MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 300. GCC LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 301. GCC LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. GCC LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 304. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. GCC LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 306. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 307. GCC LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 308. GCC LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 336. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 337. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032